Patents Examined by Jason Sims
  • Patent number: 9877961
    Abstract: Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: January 30, 2018
    Assignee: PEROSPHERE INC.
    Inventors: Solomon S. Steiner, Bryan E. Laulicht, Sasha H. Bakhru, Edith Mathiowitz
  • Patent number: 9875336
    Abstract: A computer system aligns two or more sequences with each other to identify similarities and differences between the aligned sequences. The sequences may, for example, represent proteins. The system performs alignment quickly and accurately by representing the sequences as perceptual information and conceptual information having mappings between them in a knowledgebase, and then performing the alignment based on the representations of the sequences in the knowledgebase. The alignment may be performed in polynomial time, regardless of the number of sequences that are aligned.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: January 23, 2018
    Inventors: Sherwin Han, Aihua Pan
  • Patent number: 9846762
    Abstract: Described are mathematical models and method, e.g., computer-implemented methods, for predicting tumor sensitivity to radiation therapy, which can be used, e.g., for selecting a treatment for a subject who has a tumor.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: December 19, 2017
    Assignee: University of South Florida
    Inventors: Javier F. Torres-Roca, Steven Eschrich
  • Patent number: 9827229
    Abstract: The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 28, 2017
    Assignee: INVENIO THERAPEUTICS INC.
    Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald
  • Patent number: 9829311
    Abstract: A force measurement system that includes at least one force plate module is disclosed herein. The at least one force plate module has a plurality of force plate assemblies supported on a base component, each of the force plate assemblies includes a plate component having a top surface, the top surface of the plate component forming a force measurement surface for receiving at least one portion of a body of a subject; and at least one force transducer, the at least one force transducer configured to sense one or more measured quantities and output one or more signals that are representative of the one or more measured quantities, the plate component being supported on the at least one force transducer. The at least one force plate module is configured to be connected to one or more additional force plate modules so as to form a modular array of force plates.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: November 28, 2017
    Assignee: Bertec Corporation
    Inventors: Todd Christopher Wilson, Necip Berme, Jan Jakub Ober
  • Patent number: 9792403
    Abstract: Methods and systems for analyzing genetic variants are disclosed.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: October 17, 2017
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: James Xin Sun, Roman Yelensky
  • Patent number: 9784678
    Abstract: There is provided an improved method for enhancing fluorescence images of an object, such as a biological tissue, by selectively eliminating or reducing unwanted fluorescence from fluorophores other than the fluorophore of interest. The method is based on the measurement of the lifetime of fluorophores while preserving information related to the fluorescence intensity of the fluorophore of interest.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: October 10, 2017
    Assignee: SOFTSCAN HEALTHCARE GROUP LTD.
    Inventor: Guobin Ma
  • Patent number: 9777328
    Abstract: The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: October 3, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen Quake, Hei-Mun Christina Fan
  • Patent number: 9771345
    Abstract: The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: September 26, 2017
    Assignees: Cornell University, Purdue Research Foundation, BlinkBio, Inc.
    Inventors: Francis Barany, Maneesh Pingle, Sarah Filippa Giardina, Donald Bergstrom, Lee Daniel Arnold
  • Patent number: 9763444
    Abstract: Chromene derivatives based on a chromene amide isolated from Amyris texana. Also disclosed are compositions containing chromene derivatives (synthetic or natural) based on a chromene amide isolated from Amyris texana. Also methods for repelling blood-sucking and biting insects, ticks and mites involving treating (or exposing) an object (e.g., mammals such as humans) or area (e.g., a surface such as human skin) with a blood-sucking and biting insects, ticks and mites repelling effective amount of at least one compound selected from chromene derivatives (synthetic or natural) based on a chromene amide isolated from Amyris texana.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 19, 2017
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Kumudini M. Meepagala, Ulrich R. Bernier
  • Patent number: 9757359
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 12, 2017
    Assignees: REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • Patent number: 9750731
    Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: September 5, 2017
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos Petasis
  • Patent number: 9752096
    Abstract: The present invention relates to the field of perfumery and provides certain bi-cyclo derivatives of formula (I) wherein R1 represents a hydrogen atom or a C1-2 alkyl group; R2 represents a hydrogen atom or a methyl group; and A represents a group of formula C3-5 alkanediyl group; at least one of said R1 or R2 represents a group containing at least one carbon atom. The compounds are in the form of a E or Z isomer or of a mixture thereof. These compounds are valuable perfuming ingredients capable of imparting lily of the valley and citrus notes to consumer products.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: September 5, 2017
    Assignee: Firmenich SA
    Inventor: Robert Moretti
  • Patent number: 9746461
    Abstract: A urine analyzer capable of operating in a urine measurement mode and a body fluid measurement mode, the urine analyzer includes a specimen preparing section configured to prepare a measurement specimen and a detecting section configured to derive signals of particles in the measurement specimen supplied from the specimen preparing section. A computer and a memory including programs on a computer-readable medium that enable the computer to execute operations to control the specimen preparing section and the detecting section in the urine measurement mode and in the body fluid measurement mode.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: August 29, 2017
    Assignee: SYSMEX CORPORATION
    Inventors: Masakazu Fukuda, Masamichi Tanaka
  • Patent number: 9744163
    Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 29, 2017
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
  • Patent number: 9738639
    Abstract: The present invention provides pyrroloquinoline quinone lithium salt crystal and a preparation method and application thereof. Characteristic absorption peaks appear when the diffraction angles are 6.222±0.2°, 7.379±0.2°, 7.941±0.2°, 23.631±0.2°, 24.044±0.2°, 25.497±0.2°, 27.541±0.2°, 30.736±0.2°, and 32.306±0.2° degrees in a powder X-ray diffraction pattern of the pyrroloquinoline quinine lithium salt crystal. The maximum value of thermal absorption of the pyrroloquinoline quinine lithium salt crystal appears between 90° C. and 96° C. through differential scanning calorimetry. Peaks appear when infrared spectroscopy of the pyrroloquinoline quinine lithium salt crystal is at 3396.03 cm?1, 1652.70 cm?1, 1604.48 cm?1, 1500.35 cm?1, 1355.71 cm?1, 1243.86 cm?1, 1147.44 cm?1, 808.03 cm?1, 761.74 cm?1, and 570.83 cm?1. The pyrroloquinoline quinine lithium salt polymorphism can be applied to preparation of medicines for curing memory damage.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: August 22, 2017
    Assignee: Shanghai Ri Xin Biotechnology Co., Ltd.
    Inventors: Chunjiu Zhong, Xuefeng Mei, Huan Zhang
  • Patent number: 9738629
    Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus C(HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 22, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Hongming Xie, Jiancun Zhang, Bailin Hu, Qinghong Fang, Qingyun Ren
  • Patent number: 9732087
    Abstract: Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: August 15, 2017
    Assignee: JANSSEN PHARMACEUTICA N.V.
    Inventors: Hui Cai, Frank Chavez, Paul J. Dunford, Andrew J. Greenspan, Steven P. Meduna, Jorge A. Quiroz, Brad M. Savall, Kevin L. Tays, Robin L. Thurmond, Jianmei Wei, Ronald L. Wolin, Xiaohu Zhang
  • Patent number: 9714454
    Abstract: The present invention relates to detection of materials derived from transgenic plant events. In particular, the invention provides methods, reagents, kits and reference materials for detecting the presence or absence in a sample of genetic material derived from and attributable to select transgenic plant events.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: July 25, 2017
    Assignee: Scientific Institute of Public Health
    Inventors: Marc Henri Germain Van Den Bulcke, Antoon Piet Nelly Raoul Lievens, Amaya Leunda, Etondoh Guillaume Mbongolo Mbella, Elodie Barbau-Piednoir, Myriam Jacqueline Sylviane Sneyers
  • Patent number: 9714451
    Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 25, 2017
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: John D. Shaughnessy, Jr., Bart Barlogie, Fenghuang Zhan